Phase III trial of olaparib in first-line treatment of mCRPC

Unfortunately we don’t always hear about some interesting clinical trials as early as we would like to. The following is a case in point. … READ MORE …

Talazoparib + enzalutamide in treatment of mCRPC

Back in December 2017, Pfizer started a trial to explore whether the PARP inhibitor talazoparib (Talzenna) could be used in combination with enzalutamide (Xtandi) to effectively treat men with what are known as MSI-H or dMMR subtypes of metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …

Published data on activity of olaparib in some men with mCRPC

A paper in the New England Journal of Medicine now provides detailed information about the activity of the PARP inhibitor olaparib in the treatment of carefully selected patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Olaparib continues to show promise in very late stage prostate cancer

According to a presentation at the ongoing annual meeting of the American Association for Cancer Research (AACR) meeting here in  Philadelphia, AstraZeneca’s PARP inhibiting agent — olaparib or Lynparza — continues to show promise in very late stage metastatic, castration-resistant prostate cancer. … READ MORE …

Olaparib approved in the US (but not yet for prostate cancer)

On Friday this week the U.S. Food and Drug Administration approved a drug known as olaparib (Lynparza®) for the treatment of a very specific form of very late stage ovarian cancer. This may be of interest to some men with late-stage prostate cancer. … READ MORE …

Does olaparib have real potential in treatment of mCRPC?

According to a report on the Reuters web site yesterday, some researchers are of the opinion that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (recently recommended for approval in Europe for the treatment of a subset of women with ovarian cancer) may be valuable in the treatment of some forms of prostate cancer too. … READ MORE …

Olaparib shows activity in advanced, BRCA1/2-positive prostate cancer

Apparently a drug known as olaparib (a so-called poly-ADP ribose polymerase or PARP inhibitor) has shown significant signs of activity against advanced prostate cancer in men who carry the BRCA1 and BRCA2 genes. … READ MORE …